Sharesource remote patient management – now available in 40 countries – is evolving peritoneal dialysis practice management
Two-way telehealth platform provides timely information to help clinicians better remotely manage their home patients’ therapy, including prescription changes
Sharesource also supports earlier intervention when clinical issues arise
Broad adoption of Sharesource is evidence that smarter, more effective innovation supports enhanced care options
DEERFIELD, Ill. - March 6, 2021
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced the Sharesource remote patient management platform has performed more than 5 million home peritoneal dialysis (PD) treatments globally. Sharesource is the only two-way telehealth platform offered globally – now in 40 countries – where Baxter’s Amia, HomeChoice Claria or Kaguya automated peritoneal dialysis (APD) systems are available. The platform allows healthcare professionals to remotely monitor and manage home therapy sessions from their offices, which includes the ability to change prescription settings without the patient needing to make an extra visit to the clinic.
The value of Sharesource was recently reinforced following a 7.0 magnitude earthquake that jolted Anchorage, Alaska. The earthquake caused a major highway collapse, which limited the ability of clinic staff to check on their PD patients, including those who resided within the city limits.
“When a disaster occurs, it can be scary to lose contact with and not be able to physically reach our patients who require chronic care,” said Julie Lee, R.N. Liberty & Denali Dialysis, Anchorage, Alaska. “Sharesource gave us confidence that our patients could perform their therapy sessions because even though we couldn’t reach or talk with them via phone, we were able to monitor their treatments through the platform’s dashboard.”
Healthcare professionals using the Sharesource remote patient management platform have more frequent visibility to their patients’ PD therapy sessions. According to one observational study of 733 patients using APD devices with Sharesource, the increased visibility allows clinicians to make more timely APD prescription changes1 and identify possible issues earlier.
Common issues that often cause patients to drop out of PD therapy early are catheter dysfunction and peritonitis. Early identification of abnormal PD catheter flow patterns and reduced ultrafiltration volumes using Sharesource can inform clinicians about the need to mitigate problems that can lead to suboptimal dialysis outcomes.2, 3
Recent data also show a statistically significant reduction in hospitalizations for home patients using Baxter’s Sharesource telehealth platform with an APD system.4 While many factors contribute to these findings, remote patient management technology helps support greater communication between patients and their healthcare providers, which can improve adherence to treatment and identify potential complications before they become serious. The retrospective study across 46 Baxter clinics in Colombia evaluated 90 patients using remote patient management with an APD system, in comparison to 864 patients without the telehealth technology.
“Once diagnosed with end-stage renal disease, patients initiate a medical journey that may take them through several chronic dialysis therapies,” said Laura Angelini, general manager, Baxter Renal Care business. “Sharesource’s broad global adoption is evidence that smarter, more effective innovation can offer patients and their healthcare professionals confidence and enhanced care options along the journey.”
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.
This release includes forward -looking statements concerning Amia, Homechoice Claria, Kaguya and Sharesource, including potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward -looking statements.
Baxter, Amia, HomeChoice Claria, Kaguya and Sharesource are registered trademarks of Baxter International Inc.